Questions a plan sponsor actually asks.
What is Emtricitabine, Rilpivirine Hydrochloride, and Tenofovir Disoproxil used for?
Emtricitabine, Rilpivirine Hydrochloride, and Tenofovir Disoproxil blocks HIV replication by inhibiting reverse transcriptase.
Is there a generic for Emtricitabine, Rilpivirine Hydrochloride, and Tenofovir Disoproxil?
No. Emtricitabine, Rilpivirine Hydrochloride, and Tenofovir Disoproxil is brand-only with no generic equivalents currently in market.
How much does my plan pay for Emtricitabine, Rilpivirine Hydrochloride, and Tenofovir Disoproxil?
Across 329 Part D plans, Emtricitabine, Rilpivirine Hydrochloride, and Tenofovir Disoproxil averages $130.52/unit (NADAC). Lowest available: $130.52/unit. Highest in distribution: $130.52/unit.
Is Emtricitabine, Rilpivirine Hydrochloride, and Tenofovir Disoproxil on the FDA shortage list?
No. Emtricitabine, Rilpivirine Hydrochloride, and Tenofovir Disoproxil is not currently on the FDA Drug Shortage Database.
5 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.
Same class. Different math.
Sources · every number above traces back.
Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book · NADAC unit costs: CMS NADAC weekly file (1 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.